Chen, Feiyu
Li, Haoyan https://orcid.org/0000-0002-6786-0705
Wang, Yin https://orcid.org/0000-0003-4161-1353
Tang, Ximing
Lin, Kevin
Li, Qidong https://orcid.org/0000-0002-2418-8576
Meng, Chenling
Shi, Wei
Leo, Javier
Liang, Xin
Zhang, Jie
Van, Vivien
Mahmud, Iqbal https://orcid.org/0000-0001-7729-8122
Wei, Bo https://orcid.org/0000-0001-5573-5715
Lorenzi, Philip L. https://orcid.org/0000-0003-0385-7774
Raso, Maria G. https://orcid.org/0000-0003-2105-5556
Aparicio, Ana https://orcid.org/0000-0003-0900-0923
Lu, Yue
Frigo, Daniel E. https://orcid.org/0000-0002-0713-471X
Gan, Boyi https://orcid.org/0000-0001-8884-6040
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR190021, RP230072)
U.S. Department of Health & Human Services | National Institutes of Health (CA275990, CA278889, CA275138, R01CA181196, R01CA244144, R01CA247992, R01CA269646)
Prostate Cancer Foundation (FP00016492)
U.S. Department of Defense (PC230358, W81XWH-22-1-0686)
Article History
Received: 3 November 2023
Accepted: 18 March 2025
First Online: 13 May 2025
Competing interests
: D.E.F. has received research funding from GTx and has a familial relationship with March Biosciences, Biocity Biopharmaceuticals, Hummingbird Bioscience and Barricade Therapeutics. The other authors declare no competing interests.